These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 31228618)
1. Effect of Sublingual Immunotherapy on Airway Inflammation and Airway Wall Thickness in Allergic Asthma. Hoshino M; Akitsu K; Kubota K J Allergy Clin Immunol Pract; 2019; 7(8):2804-2811. PubMed ID: 31228618 [TBL] [Abstract][Full Text] [Related]
2. Association between biomarkers and house dust mite sublingual immunotherapy in allergic asthma. Hoshino M; Akitsu K; Kubota K; Ohtawa J Clin Exp Allergy; 2020 Sep; 50(9):1035-1043. PubMed ID: 32557974 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762 [TBL] [Abstract][Full Text] [Related]
4. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778 [TBL] [Abstract][Full Text] [Related]
5. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma. Richards JR; Stumpf JL Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719 [TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis. Hoshino M; Akitsu K; Ohtawa J; Kubota K J Allergy Clin Immunol Glob; 2024 May; 3(2):100206. PubMed ID: 38328802 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis. Hoshino M; Akitsu K; Kubota K; Ohtawa J Allergol Int; 2022 Oct; 71(4):490-497. PubMed ID: 35718711 [TBL] [Abstract][Full Text] [Related]
10. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease. Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268 [TBL] [Abstract][Full Text] [Related]
11. Airway wall thickness of allergic asthma caused by weed pollen or house dust mite assessed by computed tomography. Liu L; Li G; Sun Y; Li J; Tang N; Dong L Respir Med; 2015 Mar; 109(3):339-46. PubMed ID: 25524508 [TBL] [Abstract][Full Text] [Related]
12. Serum Periostin as a Biomarker for Predicting Clinical Response to House Dust Mite Sublingual Immunotherapy in Allergic Rhinitis. Hoshino M; Akitsu K; Kubota K; Ohtawa J J Allergy Clin Immunol Pract; 2021 May; 9(5):1864-1870. PubMed ID: 33290915 [TBL] [Abstract][Full Text] [Related]
13. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432 [TBL] [Abstract][Full Text] [Related]
14. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis. Meteran H; Backer V Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839 [No Abstract] [Full Text] [Related]
15. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir. Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA Front Immunol; 2021; 12():723814. PubMed ID: 34721385 [TBL] [Abstract][Full Text] [Related]
17. [The efficacy of sublingual specific immunotherapy in children with allergic rhinitis]. Li P; Fa M; Huang ZH; Xie LS; Xu Y; Chen WB; Zhang JY; Zhang XR; Zhu Z; Li Q Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Apr; 30(7):546-551. PubMed ID: 29871066 [No Abstract] [Full Text] [Related]
18. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376 [TBL] [Abstract][Full Text] [Related]
20. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting. Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]